Jasper Ridge Partners’s CRISPR Therapeutics CRSP Stock Holding History

Jasper Ridge Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$520K	Hold	9,539	–	–	0.01%	109
2026 Q1	$454K	Hold	9,539	–	–	0.01%	103
2025 Q4	$500K	Sell	9,539 -1,138	-11%	-$68.2K	0.01%	107
2025 Q3	$692K	Buy	10,677 +3,223	+43%	+$185K	0.02%	100
2025 Q2	$363K	Hold	7,454	–	–	0.01%	114
2025 Q1	$254K	Hold	7,454	–	–	0.01%	122
2024 Q4	$293K	Hold	7,454	–	–	0.01%	118
2024 Q3	$350K	Hold	7,454	–	–	0.01%	110
2024 Q2	$403K	Hold	7,454	–	–	0.01%	110
2024 Q1	$508K	Hold	7,454	–	–	0.02%	103
2023 Q4	$467K	Hold	7,454	–	–	0.02%	104
2023 Q3	$338K	Hold	7,454	–	–	0.02%	110
2023 Q2	$418K	Hold	7,454	–	–	0.02%	103
2023 Q1	$337K	Hold	7,454	–	–	0.02%	113
2022 Q4	$303K	Hold	7,454	–	–	0.02%	110
2022 Q3	$487K	Hold	7,454	–	–	0.03%	99
2022 Q2	$453K	Hold	7,454	–	–	0.03%	102
2022 Q1	$468K	Hold	7,454	–	–	0.02%	114
2021 Q4	$565K	Hold	7,454	–	–	0.02%	110
2021 Q3	$834K	Hold	7,454	–	–	0.04%	109
2021 Q2	$1.21M	Hold	7,454	–	–	0.06%	89
2021 Q1	$908K	Hold	7,454	–	–	0.04%	88
2020 Q4	$1.14M	Hold	7,454	–	–	0.05%	75
2020 Q3	$623K	Buy	7,454 +1,970	+36%	+$175K	0.04%	86
2020 Q2	$403K	Hold	5,484	–	–	0.03%	87
2020 Q1	$233K	Hold	5,484	–	–	0.02%	89
2019 Q4	$334K	Hold	5,484	–	–	0.02%	86
2019 Q3	$225K	Hold	5,484	–	–	0.01%	87
2019 Q2	$258K	Buy	+5,484	New	+$219K	0.01%	88
2018 Q4	–	Sell	-5,484	Closed	-$243K	–	74
2018 Q3	$243K	Hold	5,484	–	–	0.01%	70
2018 Q2	$322K	Buy	+5,484	New	+$312K	0.03%	60

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jasper Ridge Partners's CRSP Position: Q2 2026 in Review

Jasper Ridge Partners held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 9,539 shares worth $520K. The position accounts for 0.01% of the portfolio, ranked #109.

Jasper Ridge Partners first reported a position in CRSP in Q2 2018 and has held it in 31 quarters since. The position peaked at $1.21M in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Jasper Ridge Partners held 9,539 shares of CRISPR Therapeutics worth $520K as of Q2 2026.
Jasper Ridge Partners left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up 0.01% of Jasper Ridge Partners's portfolio in Q2 2026, its #109 holding.
Jasper Ridge Partners first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 31 quarters since.
Jasper Ridge Partners's CRISPR Therapeutics position peaked at $1.21M in Q2 2021.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Jasper Ridge Partners's 13F filing for Q2 2026, filed 13 Aug 2026.